Beractanto is the active ingredient in a lung surfactant known commercially as Survanta.
This medicine, administered intratraceally, is indicated for the treatment of newborns with respiratory distress syndrome, as its action increases the elasticity of the lung and improves its functioning.
Beractanto is produced by Abbott Lab
Beractanto is indicated for the prophylaxis and treatment of respiratory distress syndrome, also called hialine membrane disease in newborns and premature babies.
The method of use of Beractanto consists of the administration of 100 mg per kg to newborns, intratracularly.
Treatment should be initiated as soon as possible, prevention should be initiated at least 15 minutes after delivery and rescue before completing 8 hours of life.
Four doses of the drug may be given during the first 48 hours of life, at intervals of 6 to 12 hours.
Side effects of Beractanto can be a decrease in heart rate, a decrease in the concentration of oxygen in the blood, a decrease in electrical activity of the brain and an increased risk of pulmonary hemorrhage.
It has no specific contraindications.